Ads
related to: lung cancer survival rate- View Possible Approaches
See The Need For Additional Options
In EGFRm mNSCLC. Learn More.
- A New Line Of Thinking
For When EGFR-TKI Resistance Leads
To Progression in mNSCLC. Read More
- EGFRm mNSCLC Progression
What's Next When Patients Progress
On EGFR-TKIs? Visit Site For Info.
- Addressing The Unmet Need
Learn About The Unmet Need For
Options That Can Improve Outcomes
- View Possible Approaches
Search results
‘I can’t explain why’: Does this dog dewormer cure cancer? These Facebook groups say yes
The Daily Dot· 4 days agoThree months later, the cancer had grown. From a cattle farm in Louisiana where she’s helping a...
'Disturbing' surge in young cancers may be linked to gut health, say experts
Daily Express· 1 day agoUnhealthy lifestyles, an obesity epidemic and poor gut health are feared to be fuelling a...
Why Is German Biotech Affimed Stock Soaring On Monday?
Benzinga via Yahoo Finance· 2 hours agoOn Saturday, the company announced longer follow-up data from the EGFRwt cohort and initial clinical...
Top 10 most common cancers among Blacks
Rolling Out· 5 days agoUnderstanding the most common cancers among African Americans is crucial for improving prevention, early detection, and treatment strategies.
Innovent Announces Taletrectinib(ROS1 Inhibitor)Updated Data from Pivotal Phase 2 TRUST-I Study of...
Tehachapi News· 2 days agoData were reported from 173 patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) who were treated with taletrectinib.
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma...
Benzinga· 6 hours agoWith a median follow-up of approximately three years (34.9 months), adjuvant treatment with mRNA-4157 (V940) in combination with Keytruda continued to demonstrate a clinically meaningful and ...
AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024
Morningstar· 6 days agoData From Newly FDA-Approved IMDELLTRA™ (tarlatamab-dlle) Further Reinforce Leadership in Bispecific T-Cell Engagers Overall Survival Data from Phase 3 LUMAKRAS® (sotorasib ...
Improved Outcomes With Subcutaneous Amivantamab in NSCLC
Medscape· 2 days agoSubcutaneous amivantamab plus lazertinib may offer a survival benefit over intravenous administration, alongside dramatically reduced administration times, a new study suggests.
Pfizer Highlights 'Unprecedented' 5 Year Data From Cancer Drug In Rare Form Of Advanced Lung Cancer...
Benzinga· 3 days agoAlso Read: Pfizer Agrees To Settle... Zantac. After five years of median follow-up, median...
...R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant...
Digital Journal· 11 hours agoAt a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis ...
Ads
related to: lung cancer survival rate